	US 11,707,469 B2
	Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement
Daniel Gubler, Orem, UT (US); and Michael Saunders, Orem, UT (US)
Assigned to Performance Labs Pte. Ltd., Singapore (SG)
Filed by Performance Labs Pte. Ltd., Singapore (SG)
Filed on Mar. 19, 2020, as Appl. No. 16/823,739.
Application 16/823,739 is a division of application No. 15/951,755, filed on Apr. 12, 2018, granted, now 10,624,907.
Claims priority of provisional application 62/484,676, filed on Apr. 12, 2017.
Prior Publication US 2020/0215084 A1, Jul. 9, 2020
Int. Cl. A61K 31/618 (2006.01); A61K 31/198 (2006.01); A61P 25/04 (2006.01); A61K 47/12 (2006.01); A61K 31/355 (2006.01)

CPC A61K 31/618 (2013.01) [A61K 31/198 (2013.01); A61K 31/355 (2013.01); A61K 47/12 (2013.01); A61P 25/04 (2018.01)]

7 Claims

1. A method of treating a subject in need of pain relief or aspirin-triggered resolvins cardiovascular function comprising:

identifying a subject in need of aspirin; and

providing the subject with a composition comprising a source of methyl salicylate selected from an oil from a Gaultheria sp., Betula sp., Spiraea sp. or a Polygala sp., an acetyl donor selected from d,1-alpha-Tocopherol Acetate, or an acetylated vitamin, and L-Arginine, wherein the composition is effective to produce aspirin-triggered resolvins in the subject without the deleterious effect of the aspirin or aspirin-triggered resolvins in the stomach of the subject.